EIF4EBP1 and prostate cancer: 4EBP1 expression has been found to be associated with poor prognosis in breast, colon, ovarian, and prostate cancers, and the phosphorylation of 4EBP1 seems to be associated with chemoresistance in ovarian cancer [86].